Healthcare stock prices have been pressured by election policy discussions and many believe share prices may continue to be impacted. Over the last three months (ending October 30, 2015), the overall S&P declined 1.4% while the S&P 500-Pharmaceuticals, Biotechnology and Life Sciences Index declined 6.1%, despite the defensive nature of the sector.